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INTRODUCTION 
             Stroke remains a major cause of mortality and morbidity worldwide. The  
 
burden of stroke arises largely from the elderly population which may be due to  
 
fact that a wide range of risk factors are present in them.
 
 
               There is growing evidence that high homocysteine levels contribute to the  
 
pathogenesis of ischemic stroke. Homocysteine is believed to cause atherogenesis  
 
and thrombogenesis via endothelial damage, vascular smooth muscle proliferation,  
 
and coagulation abnormalities. High homocysteine levels are associated with  
 
increased risk of cardiovascular and cerebrovascular disease.Although there are  
 
studies that show no increase in risk, there is still debate as to the strength and  
 
validity of the association. This disparity may be partly explained by  
 
methodological differences between the different studies, such as use of fasting  
 
and non-fasting samples, differing timing of sampling post-stroke and different  
 
subtypes of strokes studied. 
 
               There is a lot of research in the field of stroke in young and it’s various  
 
etiologies. Various studies are currently assessing the role of homocysteine as a  
 
independent risk factor in stroke in ischemic stroke patients and its possible  
 
implication in prevention. This study will correlate the serum homocysteine level  
 
in patients  with ischemic stroke. 
 
 
 
AIM OF THE STUDY 
 
TO STUDY THE LEVEL OF HOMOCYSTEINE IN ACUTE ISCHEMIC  
STROKE AND TO FIND THE CORRELATION BETWEEN   
HYPERHOMOCYSTEINEMIA AND ACUTE ISCHEMIC STROKE  
                                           REVIEW OF LITERATURE 
 
          Stroke is one of the major cause of mortality and morbidity worldwide,  
with ischemic stroke being the predominant type all over the world. With the  
current ageing population, ischemic stroke burden will inevitably increase  
leading to increasing demand for more effective prevention, diagnosis, and  
treatment strategies.About 15 million people are affected by stroke worldwide and  
out of this one thirds die and one thirds  are left permanently disabled. Stroke is  
defined as “rapidly developed signs of focal or global disturbance of cerebral  
function lasting longer than 24 hours(if not interrupted by death) with no apparent  
non-vascular cause” by the WHO3. 
                                          
DEFINITION OF ISCHEMIC STROKE  SUBTYPES 
 There are two commonly used classification systems for ischemic     
 
 stroke. 
 
1)THE OXFORDSHIRE COMMUNITY STROKE PROJECT 
 
2)THE TRIAL OF ACUTE STROKE TREATMENT  
 
   CLASSIFICATION SYSTEMS. 
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OXFORDSHIRE COMMUNITY STROKE PROJECT CLASSIFICATION 
 
 The OCSP classification categorized ischemic stroke according to 
 
 clinical presentation into  four  subtypes based  on initial symptoms, 
 
 providing an estimation of  magnitude    and location of cerebral     
 
 infarct: 
 
 1.total anterior circulation infarct  
 
 2.partial anterior circulation infarct  
 
 3.posterior  circulation  infarct  
 
4. lacunar infarct  
 
 
 
19
TRIAL OF  ACUTE STROKE TREATMENT  CLASSIFICATION 
 
 The TOAST classification categorized ischemic stroke according to  
 
 pathology into five subtypes based on clinical symptoms,  
 
 neuroimaging data, and other diagnostic tests  
 
 1.large-vessel  disease – large  extra-cranial or intra-cranial artery  
 
stenosis usually of atherosclerotic nature 
 
 2. small-vessel disease – equivalent to  a lacunar  infarct within the  
 
     white  matter and deep grey matter in the brain 
 
 3.cardioembolic stroke–arterial thrombus or embolus of cardiac 
origin 
 
4.stroke  of  other  determined etiology 
 
5.stroke of undetermined etiology – there  are two possible causes,  
 
a)no identified causes 
 
b) incomplete  investigation. 
 
 
EPIDEMIOLOGY 
 
          Statistics from all over the world shows that 14 million people suffer a  
 
stroke every year out of which 1/3 die and 1/3 are left permanently  
 
disabled
1
. 
 
           In India, prevalence rate of stroke range from 84-262/100,000 in  
 
rural and 334-424/100,000 in urban areas. The incidence rate is 119-145/100,000  
 
based on the recent population based studies. There is also a wide variation in case  
 
fatality rates with the highest being 42% in Kolkata among the stroke registries in  
 
Kolkata, Bangalore, Mumbai and Trivandrum
1
. 
 
 
 
 
 
 
Mortality following a stroke
17 
 
 
 
RISK FACTORS 
 
Modifiable risk factors 
 
The modifiable risk factors are  high blood pressure, diabetes mellitus, cardiac  
 
diseases(such as AF, heart failure, and MI), high cholesterols, cigarette smoking,  
 
alcohol consumption, obesity, sedentary lifestyle, and unhealthy dietary habits  
 
Increased blood pressure contributes greatly to stroke  and its proper management  
 
lead to a significant reduction of stroke incidence and recurrence
22
. This is very  
 
much seen with cigarette smoking also. 
 
High total cholesterol and low-density lipoprotein and low high-density lipoprotein  
 
had been associated with increased risk of  myocardial infarction  but this  
 
increased risk is more modest among ischemic stroke. Beneficial effect is seen  
 
with moderate consumption of  alcohol. However, high alcohol consumption has  
 
the opposite association and is a risk factor, possibly acting through elevation of  
 
blood pressure and subsequently cardiac diseases. High salt intake and lack of  
 
physical activity also contribute towards stroke risk. Moderate- to heavy-intensity  
 
physical activity had been shown to have protective effect against ischemic stroke. 
 
 
 Non-modifiable risk factors 
 
Age, gender, ethnicity are non-modifiable risk factors. Age is the strongest risk  
 
factor for stroke; stroke risk has an approximately two-fold increase with every  
 
increasing decade after the age of 55 years
4
. Men have a higher stroke  
 
incidence and mortality compared to women.However, with the considerable  
 
elevation of stroke rates in older age group, more women are suffering from this  
 
condition as women tend to live longer
4
. Different ethnic groups have shown  
 
different stroke incidence and different stroke subtypes. Asians, African Americans  
 
and Hispanic Americans are shown to have higher incidence compared to the  
 
Caucasians
20
. Intracranial atherosclerosis is more prevalent among the Asians,  
 
Africans Americans, and Hispanics Americans, while extra cranial carotid stenosis  
 
is most common among Caucasians. Genetic predisposition to stroke had been  
 
demonstrated in family history and twin studies, and this is especially prominent  
 among younger individuals
21
. 
 
 
 Other risk factors 
 
Inflammation, infection, hypercoaguable states, usage of hormone replacement 
 
therapy and oral contraceptives, and socioeconomic factors are some of the    
 
potential risk factors that have been been associated with ischemic stroke. 
 
 
EVALUATION OF STROKE
4
  
When a stroke patient is brought to the casualty,the ABC s of the patient should  
be stabilized ie the airways ,breathing  and the circulation should be taken care of  
which  is followed by a quick neurological assessment of the patient  
and the associated comorbidities present in the patient.When a patient presents  
with ischemic stroke like symptoms,we should first rule out other common  
conditions such as hypoglycaemia ,seizures ,hypertensive encephalopathy and  
other stroke like conditions, since these conditions can be easily treated. 
 
FEATURES OF CLINICAL CONDITIONS  MIMICKING STROKE
2 
1.Seizures -   seizures noted, witness history, postictal state 
2.Hypoglycaemia – h/o diabetes,low blood glucose,altered sensorium 
3.Complicated migraine- h/o preceding aura, u/l headache 
4.CNS abscess – headache,fever,endocarditis 
5.CNS tumour- headache,slow progression,primary at another place 
6.Drug intake- lithium,phenytoin 
7.Psychogenic- inconsistent examination findings 
8.Wernickes encephalopathy -  c/c alcoholism,ataxia,confusion 
9.Hypertensive encephalopathy- uncontrolled hypertension,  headache, seizure,                         
cerebral oedema 
 
 
PATIENT HISTORY 
It is very important to ascertain the time of onset of the stroke symptoms from the  
patient since this is most important piece of history on which further treatment and  
management of the patient depends. 
The time of onset of stroke is made out as when the patient was at his or her  
previous baseline or symptom-free phase. For patients who are unable to provide  
this information such as patients who suffered a stroke during their sleep or who  
was found unconscious somewhere the time of onset of stroke is taken as when the  
patient was last known to be awake and symptom-free or known to be normal. 
 
4
The symptoms that one should carefully ask for in a case of ischemic stroke are  
1.sudden weakness  
2.sudden speech disturbances 
3.sudden visual loss 
4.sudden dizziness  
4.sudden,severe headache . 
The FAST ie face, arm, speech, time protocol is being followed now. 
  
GENERAL EXAMINATION 
 
On admission,  a complete physical examination is carried out on the patient by a  
 
physician or a neurophysician and a complete neurological workup and  
 
examination is done. Initially like all patients received in the casualty, the  
 
patients airway ,breathing and circulation should be checked and the vitals such as     
 
heart rate, blood pressure, temperature and oxygen saturation should be carefully  
 
assessed and stabilized. 
 
The main goal of general examination is to identify  the cause of stroke in the  
 
patient and to assess the signs and symptoms in the patient in relation to the stroke  
 
such as presence of any signs of trauma on the head or a tongue bite in relation to a  
 
seizure,carotid bruit, any cardiac murmurs,arrhythmias or look for any signs of  
 
coagulopathy  or emboli such as Osler nodes or Janeway lesions. 
 
 
4
IMMEDIATE DIAGNOSTIC STUDIES TO BE DONE IN A CASE OF  
 
ACUTE ISCHEMIC STROKE  
 
ALL PATIENTS 
 
1.CT OR MRI BRAIN 
 
2.RANDOM BLOOD SUGAR 
 
3.CBC 
 
4.RENAL FUNCTION TESTS 
 
5.SERUM  ELECTROLYTES 
 
6. SP O2 STATUS 
 
7.ELECTROCARDIOGRAM 
 
8.PT/APTT/INR 
 
IN SELECTED PATIENTS 
 
1.LIVER FUNCTION TESTS 
 
2.PREGNANCY TESTS 
 
3.BLOOD ALCOHOL LEVEL 
 4.ABG ANALYSIS 
 
5.TOXICOCLOGY SCREEN 
 
6.CHEST XRAY 
 
7.EEG (IF SUSPECTING ASSOCIATED SEIZURES) 
 
8.LUMBAR PUNCTURE( IF SAH IS SUSPECTED 
 
9.TT TIME IF THE PATIENT IS TAKING DIRECT THROMBIN OR DIRECT  
    
   FACTOR Xa INHIBITORS 
 
 
GENERAL SUPPORTIVE CARE 
 
Airway and Ventilatory Support 
In a patient with ischemic stroke,there  is a chance of decreased tissue oxygenation  
and energy supply to the periphery due to the concomitant presence of hypoxemia  
and hypotension and, if present,it should be always be corrected to limit further  
damage at a cellular level.Hence a constant reassessment of  the ABCs of the  
patient is required. 
Hypoxia
23 
 
Hypoxia is a very frequent finding after stroke and usually a stroke patient,  
 
develops hypoxia within 48 hours of stroke onset. Common causes of hyoxia in a  
 
stroke patient include obstruction of the airways,decreased work of breathing and  
 
aspiration due to loss of consciousness and associated pneumonia due to secondary  
 
infections.Since there is an loss of oropharyngeal mobility and upper airway  
 
protective reflexes in the unconscious,they are at an increased risk to develop  
 
respiratory complications.When the oxygen saturation falls to dangerously low  
 
levels, the patients develop Cheyne-Stokes respiration[central periodic  
 
breathing].  
 
 
Patient Positioning
24
  
 
The position of the patient is of utmost importance since it can affect the oxygen  
 
saturation,the cerebral perfusion pressure, the MCA mean flow velocity, and  
 
intracranial pressure.The supine position is the best for stroke patients as it has a  
 
very minute effect on oxygen saturation and also increases the perfusion of he  
 
cerebral vessels.The head end of the patient should be elevated to about 15 to 30  
 
degrees to prevent any aspiration and also in those suspected to have increased  
 
intracranial pressure.  
 
Oxygen Maintenance
24 
 
In a patient with ischemic stroke, there may be a gradual improvement of the  
 
neurological defecits if  oxygen  is started within 12 hours of onset.The oxygen  
 
saturation of the patient  should be maintained above 94% and oxygen can be  
 
given via a nasal cannula or a Venturi mask. If the patient is haemodynamically  
 
unstable then oxygenation is done via continuous positive airway pressure, or  
 
endotracheal intubation with mechanical ventilation which can decrease  
 
intracranial  pressure or brain edema if present. 
Temperature
25 
 
Hyperthermia 
 
Hyperthermia in stroke patients usually indicate  a  secondary infection such as  
 
pneumonia or urinary tract infection or an ongoing sepsis or could be due to a  
 
pontine stroke.It is usually present in more than one – third of stroke patients and if  
 
present it usually denotes a poor neurological outcome  due to increased  
 
production of free radicals or increased release of neuro transmitters and any  
 
hyperthermia in stroke patients should be immediately investigated  and treated  
 
accordingly.Antipyretics are useful to reduce the temperature in  
 
such cases and aspirin also has a thermoregulatory action and helps in achieving  
 
the normal temperature. 
 
 
Heart monitoring 
 
Stroke patients have a very high probability of  sustaining a number of cardiac  
 
arrythmias and hence it would be ideal that they undergo continuous cardiac  
 
monitoring from the time of admission up until 24 hours after stroke. This will help  
 
in the detection of any atrial fibrillation, supraventricular tachycardias or any other  
 
arrythmias during stroke and can be accordingly treated. 
 
 
 
 
 
 
Blood Pressure 
 
Hypertension 
 
Arterial blood pressure  varies significantly in stroke patients and it can have  
 
significant clinical consequences.Usually all ischemic stroke patients have an  
 
increased blood pressure if the stroke patient had hypertension before the onset of  
 
stroke then the blood pressure will be much higher compared to an a patient who  
 
didn’t have hypertension before stroke.After that the blood pressure  starts  
 
decreasing in about 1 and half hour after stroke.Very high blood pressure is highly  
 
detrimental to the patient as it can lead to hypertensive encephalopathy, multiple  
 
arrhythmias  and renal failure. It can also increase the already present cerebral  
 
edema or can lead to the hemorrhagic transformation of the infarcted tissue.Very  
 
high blood pressure can also decrease the blood supply to the other major organs  
 
and also the brain exacerbating the ischemic insult. Slight increase in blood  
 
pressure is helpful for the patient since it help in increasing blood flow to the  
 
ischemic tissue. 
 
4The blood pressure shouldn’t be decreased during the initial period of stroke   
 
unless the blood pressure is >220/120 mm Hg or there is an associated medical  
 
disability,for example acute coronary syndrome, heart failure or aortic dissection  
 
that requires the blood pressure to be lowered drastically for the well being of the  
 
patient.In such conditions, the blood pressure should be lowered by 30% of the  
 
mean arterial pressure or 15% of the systolic blood pressure and during this  
 
reduction the patient should be checked for any neurological deterioration.If  
 
fibrinolytic therapy is to be started for the patient,then the blood pressure should be  
 
brought down to 185/110.The blood pressure should be maintained at this level or  
 
below during and after fibrinolysis to decrease the risk of intracranial haemorrhage  
 
in the patient.  
 
 
4
BLOOD PRESSURE CONTROL BEFORE THROMBOLYSIS 
 
 If BP is less than 185/110,the patient  can be taken up for reperfusion therapy 
 
 and if BP is above 185/110,then administer, 
 
 1.LABETALOL at the rate of 10-120 mg iv over one to two minutes ,and if  
 
        recquired repeat once more 
 
     2.Next  NICARDIPINE  can be tried, about 5mg/hr infusion and can be titrated  
 
        upto to a maximum of 15mg/hr by titrating by 2.5mg/hr every 15 minutes and  
 
        then adjust to maintain the blood pressure 
 
3.Other agent which can be used to decrease the blood pressure are  
 
   hydralazine,enalaprilat etc. 
 
4.If the blood pressure is not maintained below 185/110 ,rtPA should not be    
 
   administered.   
 
 
 
 5
MANAGEMENT OF BLOOD PRESSURE DURING AND AFTER             
REPERFUSION THERAPY 
 
 1.The blood pressure should be checked every fifteen minutes from the start of  
 
   the infusion for a period of two hours,then every 30 minutes for the next six  
 
  hours and then every hour for sixteen hours. 
 
 2.If the systolic blood pressure is greater than 180-230 or the diastolic blood  
 
        pressure is greater than 105 – 120 , the following drugs can be used  
   
a) Labetalol 10 mg iv loading dose followed by continuous infusion at the  
 
rate of 2 – 8 mg/min. 
  
        b)Nicardipine , about 5mg/hr infusion and can be titrated  
 
          upto to a maximum of 15mg/hr by titrating by 2.5mg/hr every 5 - 15 minutes  
 
        c)Finally if the bood pressure is not controlled ,iv sodium nitroprusside can be  
 
          tried. 
 
 
Hypotension
26 
 
A patient with acute ischemic stroke episode is usually never hypotensive but if  
 
hypotension is present, then any associated comorbidities such as acute myocardial  
 
infarction , aortic dissection or shock should be present.The brain  vulnerable to  
 
any hypotensive episodes since there is impaired cerebral autoregulation during  
 
acute ischemic stroke. Arterial hypotension on admission in acute ischemic stroke  
 
patients is associated with poor outcomes.The associated comorbidities should be  
 
urgently treated so as to reduce the extent of brain damage due to  
 
hypotension.Ideally intravenous fluid should be used to correct the hypotension but  
 
if resistant to treatment,the vasopressor agents such as dopamine and noradrenaline  
 
should be tried next.  
 
 
Intravenous Fluids
27 
 
Patients who had suffered an acute ischemic stroke episode are either hypovolemic  
 
or euvolemic.Hypovolemia is highly detrimental to the patient as it can decrease  
 
the perfusion of the brain and increase the area of infarct, lead to further  
 
thrombosis and can also lead to other major organ damage such as renal  
 
insufficiency. At the other end of the spectrum ,hypervolemia can increase the  
 
brain oedema and also increase the stress on the myocardium.Thus an euvolemic  
 
status should be always attained in an ischemic stroke patient. 
4
For patients who  
 
present with euvolemia, maintenance intravenous fluids should be initiated which  
 
is calculated  to be about 30 mL/kg of body weight.For stroke patients who are  
 
hypovolemic,there should be rapid replacement of the intravascular volume  
 
followed by maintenance intravenous fluids therapy and extra precaution is to be  
 
taken in those who are susceptible to intravascular volume overload, such as those  
 
patients with renal or cardiac failure.  
If hypotonic solutions such as 5% dextrose or 0.45% saline is instituted to the  
patient,it is  redistributed to the intracellular spaces which in turn can exacerbate  
the brain edema and therefore  isotonic solutions such as 0.9% saline which is  
distributed only into the extracellular spaces should be used for patients with acute  
ischemic stroke. 
 
Blood Glucose 
 
Hypoglycemia 
If a stroke patient is found to be hypoglycaemic it may be due to a prolonged  
fasting state or if the patient was on anti diabetic medications.If hypoglycemia is  
severe, it will cause both autonomic and neurological symptoms, which are readily  
reversible if it is treated rapidly. However, severe or prolonged hypoglycemia can  
result in irreversible brain damage and the low levels should be treated as soon as  
possible.In a healthy individual,autonomic symptoms ie  sweating trembling or  
anxiety  appears in the patient when the blood glucose level falls below 57 mg/dL,  
and symptoms of brain dysfunction ie disorientation, slowing of speech or  
dizziness appears when the glucose level drops below 47 mg/dL
4
 .However, in  
ischemic stroke patients with poorly controlled diabetes, these symptoms occur at   
higher blood glucose levels and in some cases brain dysfunction occurs before the  
autonomic symptoms. Hence it is of paramount importance that the hypoglycaemia  
is corrected as early as possible which is usually done by an intravenous push of 25  
mL of 50% dextrose. 
 
Hyperglycemia 
 
Ischemic stroke patients who are diabetic are mostly found to have high blood  
 
sugar at the time of admission which may be  due to a stress reaction  and release  
 of catecholamines with impaired glucose metabolism.Ischemic stroke patients with  
 
hyperglycaemia are associated with a poor prognosis.The glucose levels of these  
 
patients should be maintained within the range of 140 to 180
4
 with the help of  
 
subcutaneous insulin and further care should be taken that there is no over  
 
correction such that it can lead to hypoglycaemia. 
 
Neurological Examination and Stroke Scale/Scores
6 
There are a number of stroke scales available which helps in the quantification of  
the neurological deficit and can also assess the prognosis of the stroke  
patients.The most commonly used ones is the  National Institute Of Health  
Stroke Scale(NIHSS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NATIONAL INSTITUTE OF  HEALTH  STROKE SCALE 
 
 
 
 
 
SOME SELECTED STROKE SCORING SYSTEMS
7 
 
 
 
EARLY DIAGNOSIS – BRAIN AND VASCULAR IMAGING 
In a stroke patient, time is precious  and brain imaging should be immediate so  
as to not only diagnose and find the cause but also to institute timely reperfusion  
therapy.An early brain imaging helps to identify the location ,the size ,the  
vascular territory of the infarct ,the presence or absence of any haemorrhage and  
the presence of any brain oedema.Although there a number of  imaging  
techniques available in this modern era,non–contrast-enhanced computed  
tomography (NECT) is the most widely used one and ample to diagnose  
ischemic stroke and also to find out the indication and contraindication for  
fibrinolysis which  allows patients with ischemic stroke to receive timely  
fibrinolytic therapy and  CT should be ideally taken within 25 minutes of the  
patient’s arrival to the casuality4. 
 
 
Parenchymal Brain Imaging 
 
NECT and Contrast-Enhanced CT Scans of the Brain 
 
CT brain can identify almost all cases of  intracranial hemorrhage and can also find  
 
the presence of brain tumour and hence is useful to exclude the contraindications  
 
of fibrinolytic therapy.
4
A CT can be used to visualize the presence of any  
 
parenchymal damage within 3 hours but one of its disadvantage is that it is not  
 
sensitive enough to pick up any acute and small cortical or subcortical infarctions,  
 
especially those present in the posterior fossa.Despite these disadvantages, its  
 
widespread immediate availability,ease of interpretation, and speed of  
 
retrieval,makes CT the most commonly used  imaging modality in acute ischemic  
 
stroke. 
 
NECT can identify early signs of ischemic injury  or arterial occlusion.The  
 
common signs of cerebral ischemia that are seen very early are
4
  
 
a) loss of gray-white differentiation  
 
b)  loss of distinction of the basal ganglia nuclei (lenticular obscuration)  
 
 
c)  blending of the densities of the cortex and underlying white matter in the  
 
insula (insular ribbon sign) and over the convexities (cortical ribbon sign)  
 
d)  swelling of the gyri that produces sulcal effacement 
 
e)  increased density within the occluded artery ie hyperdense middle  
           
          cerebral artery (MCA) sign, which is indicative of large-vessel     
 
          occlusion 
 
     g)  Hyperdense MCA “dot” sign is a clot within a branch of the MCA  
            
          smaller than the thrombus volume in the MCA and hence a better  
 
          target for intravenous fibrinolysis.  
 
     h) The  hyperdense basilar artery sign.  
 
 
 
                
                                        
                                          DENSE MCA SIGN 
                        
 
                                 HYPERDENSE MCA SIGN 
 
                               
                                      
                                     LOSS OF INSULAR RIBBON 
 
                                  
 
                                 HYPERDENSE BASILAR ARTERY SIGN 
 
MRI of the Brain 
 
4
Standard MRI sequences such as T1 weighted, T2 weighted, fluid-attenuated  
 
inversion recovery [FLAIR]) don’t usually pick up the changes of acute ischemia.  
 
Diffusion-weighted imaging (DWI) is the most sensitive and specific imaging  
 
technique for acute infarct,much better than NECT or any other MRI  
 
sequence. DWI correctly identifies lesion size, site, and age. DWI can also pick up  
 
small cortical lesions and small deep or subcortical lesions, including those in the  
 
posterior fossa, areas which are poorly visualized with standard MRI sequences  
 
and NECT. DWI can identify satellite ischemic lesions that provide information on  
 
possible stroke mechanism. 
 The artery susceptibility sign is the magnetic resonance (MR) counterpart of   
 
hyperdense MCA seen on NECT
4
. 
 
Conventional MRI is more sensitive than NECT in identifying both new and  
 
preexisting ischemic lesions.DWI-positive lesions tend to be smaller and multiple  
 
in patients with TIA. 
 
In the evaluation of acute stroke patient including identifying candidates  
 
for fibrinolytic treatment,MRI can be used as the sole imaging modality.Gradient  
 
MR echo sequences has the ability to detect  silent prior microbleeds not picked up  
 
by NECT. These  microbleeds represents markers of bleeding-prone angiopathy  
 
and  may be associated with an increased risk of hemorrhagic transformation after  
 
antithrombotic and fibrinolytic therapy 
The advantages of MRI compared with NECT for parenchymal imaging are
4
  
1. Differentiating acute from chronic ischemia;   
2. Identifying acute, small cortical, small deep, and posterior fossa infarcts;  
3. Identification of subclinical satellite ischemic lesions  
4.The avoidance of exposure to ionizing radiation 
5.Greater spatial resolution.  
Disadvantages of MRI are  
1. Cost  
2. Long duration of the test 
3. Limited availability 
4. Increased susceptibility to motion artifacts  
5. Patient contraindications such as claustrophobia,cardiac pacemakers,or metal 
    implants 
Intracranial Vascular Imaging 
 
Most of large strokes are caused by occlusion of more than one  large vessel which  
 
are devastating hence detection of large-vessel occlusion by intracranial vascular  
 
imaging  improves the ability to make just clinical decisions.Large-vessel  
 
occlusion can be identified by NECT.The length of clot within the middle cerebral  
 
artery is directly related to the success of recanalization with intravenous  
 
fibrinolysis.  
 
CT Angiography 
 
CT angiography (CTA) helps to assess the intra and extracranial vessels in acute,  
 
subacute, and chronic stroke  and conveys  information about the presence or  
 
absence of vessel occlusions or stenosis. The CTA is able to detect the stenosis and  
 
occlusions in the large vessels but is not able to detect the flow rates and direction  
 
of flow of blood which is provided by digital substraction angiography.CTA  
 
andMRI/DWI are comparable for detecting ischemic regions, with DWI better at  
 
bringing out smaller abnormalities and those in the brainstem and posterior  
 
fossa.In early strokes ie less than 3 hours, CTA accurately predicts the volume of  
 
tissue that will ultimately become infarcted which is not with the case with   
 
NECT.CTA gives an estimate of cerebral blood volume rather  than the expression  
 of cytotoxic edema seen on NECT. 
 
MR Angiography(MRA) 
 
Intracranial MR angiography is performed along with brain MRI and helps in  
 
therapeutic decision making. 
 
Conventional Angiography 
 
Digital substraction angiography(DSA) is the “gold standard”  imaging modality  
 
for many types of cerebrovascular lesions.The resolution, sensitivity, and  
 
specificity of DSA  is higher than those of the noninvasive techniques, but  DSA is  
 
an invasive test and can cause major complications such as stroke and  
 
death.Cerebral angiography should not be the initial imaging modality of choice    
 
for emergency  evaluation of stroke because of the time necessary to perform the  
 
examination,a CTA or MRA can be done in an additional 2 to 4 minutes during  
 
initial stroke work up and can negate the need for catheter angiography.  
 
Extracranial Vascular Imaging 
 
The extracranial blood vessels should be screened to not only find out the cause of  
 
stroke but also to prevent recurrences. To find out the degree of stenosis and for  
 
determination of eligibility for CEA or carotid angioplasty and stenting, 
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DSA is  
 
the “gold standard” imaging modality.CTA  and multimodal MRI are best for  
 
detecting dissection.A very high-grade stenosis  (“string sign”) is best  detected by  
 
DSA, followed closely by contrast-enhanced MRA and CTA.  
 Carotid Doppler Ultrasound 
 
Carotid Doppler  ultrasound is a safe imaging modality for the detection any  
 
stenosis in the carotids andand measuring blood velocities. Doppler measures that  
 
have been correlated with angiographic stenosis include 
 
 1.end-diastolic velocity  
  
 2.internal carotid artery peak  
 
 3.systolic velocity    
 
 4.ratios of internal carotid artery and common carotid artery peak systolic    
 
    velocity. 
 
CT Angiography 
 
CTA is a sensitive, specific, and accurate technique for imaging the extracranial  
 
vessels and is superior to carotid ultrasound in differentiating a carotid occlusion  
 
from a very high-grade stenosis. 
 
Conventional Angiography 
 
DSA is the best imaging technique for cervical carotid and vertebral arteries,  
 
particularly when invasive therapies are considered.It can also provide information  
 
about collateral flow, perfusion status, and other occult vascular lesions that can  
 
affect patient treatment. 
 
 
 
 
 Perfusion CT and MRI 
 
 It has become paramount that the information about the nature and severity of the  
 
 ischemic injury is  as important as the “time” of the ischemic event for predicting  
 
 outcome  and prognosis and in making judicious therapeutic judgments.It is now  
 
 stated that the ischemic salvageable “penumbral” tissue should be a target for  
 
 reperfusion and neuroprotective strategies but requires proper patient selection.  
 
 Brain perfusion imaging techniques  provide  information about regional cerebral  
 
 hemodynamics in the form of  cerebral blood volume, cerebral blood flow and  
 
 mean transit time.. Perfusion imaging can very much indicate areas that are  
 
 severely and irreversibly infarcted.Advantages of the  CT over MRI include large  
  
 scale availability of emergency CT imaging, quick imaging, and fewer  
 
 contraindications to CT versus MRI.  Disadvantages of the CT over MRI include  
 
the use of ionizing radiation and iodinated contrast which carries a risk of  
 
nephrotoxicity. Use of low-osmolar or iso-osmolar contrast minimizes this  
 
risk.Another disadvantage is limited brain coverage  which is overcome by the  
 
latest 256- and 320-slice CT. 
 
Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy is caused by  
 
gadolinium-based contrast agents and hence are generally  avoided in the presence  
 
of advanced stages of renal failure with estimated glomerular filtration rate <30  
 
mL/min/m
2
.Arterial spin labeling can be used to negate the need of gadolinium  
 contrast material.  
 
TREATMENT 
 
Intravenous rtPA 
Intravenous fibrinolytic therapy for acute stroke is the best treatment available.The   
Only FDA approved drug for intracranial fibrinolysis is reteplase.Reteplase is a  
recombinant form of human plasminogen activator which is non glycosylated .It  
has a longer half life than other tissue plasminogen activator due to its amino acid  
chain modification.Its half life is about 13 – 16 minutes.Since reteplase can easily  
penetrate inside the formed thrombus,it can produce an enhanced fibrinolytic  
activity,which will allow for rapid perfusion and decreased chances of 
bleeding. 
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Inclusion and Exclusion Characteristics of Patients With Ischemic Stroke  
Who Could Be Treated With IV rtPA Within 3 Hours 
INCLUSION CRITERIA 
Patient presenting with ischemic stroke 
Presentation less than 3 hours from the time of onset of symptoms 
Age greater than 18 years 
EXCLUSION CRITERIA 
History of head trauma or stroke within a period of  3 months 
Symptoms suggestive of  subarachnoid haemorrhage 
Previous history of intracranial haemorrhage 
Any history of  intracranial aneurysm,neoplasm 
Any recent history of intracranial or intraspinal surgery 
High blood pressure  greater than 185/110 
Any active internal bleeding 
Platelet less than 100000/mm3 
Elevated a PTT due to heparin administration within 2 days  
History of anticoagulant intake which raises INR greater than 1.7 or PT greater  
than 15 seconds 
Random blood sugar less than 50mg/dl  
CT brain which shows infarction greater than 1/3 rd cerebral hemisphere. 
Patient taking direct thrombin inhibitors or direct factor Xa inhibitors with  
elevated aPTT,PT,TT etc 
 
RELATIVE EXCLUSION CRITERIA 
Pregnancy 
History of seizures at the onset of stroke with post ictal residual symptoms. 
Rapidly improving neurological symptoms 
 History of  recent myocardial infarction within a period of 3 months 
 History of  major trauma or surgery within a period of 14 days 
 History of recent urinary or gastrointestinal haemorrhage within a period of 3      
 weeks. 
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Additional inclusion and exclusion characteristics of patients with acute 
ischemic stroke who could be treated with iv rtPA within 3-4.5 hrs from 
symptom onset 
 
INCLUSION CRITERIA 
 
Ischemic stroke presenting with neurological defecit 
 
Patient presenting within 3 – 4.5 hours of symptom onset 
 
RELATIVE EXCLUSION CRITERIA 
 
Age greater than 80 years 
 
NIHSS greater than 25 indicating severe stroke 
 
History of oral anticoagulant intake  
 
History of both prior stroke and diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRAVENOUS rtPA 
 
4
STEPS FOR INFUSION OF RETEPLASE 
 
1.0.9 g/kg to a maximum of 90 mg is infused over a period of 1 hour ,out  of which     
 
    10% of this is given as loading dose over a period of 1 minute. 
 
2.During the infusion, if the patient develops headache,hypertension,vomiting  or if  
    
   there is a worsening of neurological symptoms,the infusion is discontinued and  
 
   an urgent CT SCAN is taken. 
 
3.The patient is assessed for any neurological deterioration every fifteen minutes  
 
   during and after infusion for a period of two hours,followed by every half an  
 
   hour for six hours  and then hourly until 24 hours after IV treatment. The blood  
 
   pressure  should be also be checked in this manner. 
 
4.The frequency of blood pressure measurements should be increased if the blood   
 
   pressure is above 180/105.If the blood pressure is high, anti-hypertensive  
 
   medications should be administered. 
 
5.CT / MRI scan should be taken 24 hours after reteplase infusion prior to starting  
    
   anticoagulants or antiplatelets. 
 
6.Insertion of catheters,nasogastric tubes should be delayed if the patient can be  
 
   managed without these. 
 
 
 
 
 
Anti-platelets 
Oral Agents 
 
Aspirin is the antiplatelet agent that has been used most widely and helps in the  
 
prevention of recurrent events.Aspirin is usually used in a dose of 75-325 mg daily  
 
and is associated with a 22% reduction of recurrent stroke
28
.It is a irreversible  
 
cyclooxygenase inhibitor and usually starts acting within 2 hours. Clopidogrel or  
 
dipyridamole are not commonly used in the setting of acute stroke since  treatment  
 
with clopidogrel with a daily dose of 75 mg  produces maximum inhibition of  
 
platelet aggregation only after five days. This delay presents a problem for an early  
 
treatment effect in the management of patients with acute ischemic stroke. 
 
 
NEUROPROTECTIVE AGENTS 
Neuroprotection is the technique of applying a therapy that directly affects the  
 
brain tissue to reclaim or delay the infarction of the viable ischemic  
 
penumbra,rather than reperfusing the tissue.There are are a number of  
 
pharmacological agents that restrict the cellular effects of acute ischemia or  
 
reperfusion  and may limit neurological injury after stroke.
29
Citicoline, a  
 
phospholipid precursor that stabilizes the cell membranes is one  of the most  
 
widely used neuroprotective agent.In addition to their LDL–lowering effects,  
 
statins, or HMG-CoA reductase inhibitors also exert  neuroprotective properties  
 
such as favourable effects on endothelial function, cerebral blood flow, and  
 
inflammation. 
 HOMOCYSTEINE AND STROKE 
 
Homocysteine is a unique sulfur-containing amino acid which is necessary for one-                       
 
carbon metabolism. It is the homologue of the amino acid cysteine, from which it  
 
differs  by an additional methylene bridge (-CH2-). It is synthesized  
 
from methionine by the removal of the terminal methyl group. Homocysteine can  
 
 converted into methionine or cysteine. 
  
                            
 
 
HOMOCYSTEINE METABOLISM 
 
30
Homocysteine is not synthesized  from the food we eat. Instead, it is synthesized  
 
from methionine via a complex process. Firstly, methionine receives an adenosine  
 
moiety from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to  
 
give S-adenosyl methionine(SAM). SAM then transfers the methyl group to an  
 
acceptor molecule, ( norepinephrine as an acceptor during epinephrine  
 
synthesis, DNA methyltransferase as an intermediate acceptor in the process  
 
of DNA methylation). The adenosine part is then hydrolyzed to yield L-  
 
homocysteine. L-Homocysteine has two primary fates: conversion 
 
via tetrahydrofolate (THFA) back into L-methionine or conversion to L-cysteine.  
 
Homocysteine is metabolized by any one of  the two pathways: remethylation or  
transulfuration  which is shown diagrammatically below
31
. 
.  
                                  
 
LIFESTYLE AND PHYSIOLOGIC DETERMINANTS 
Homocysteine level increases  with age,and is higher in men and depends on 
 
renal function. Renal dysfunction raises plasma homocysteine levels  
 
by reducing homocysteine excretion . Homocysteine levels are also increased in  
 
male sex, smoking , high intake of  coffee,sedentary lifestyle,alcohol consumption  
 
and old age.  
 
Nutrition 
Nutritional deficiencies in vitamin dependant  cofactors which are required for  
 
homocysteine synthesis, such as folic acid, cyanocobalamin,riboflavin  and  
 
pyridoxine can lead to hyperhomocysteinemia . 
 
Genetic Determinants 
A thermolabile variant of N
5
,N
10
-methylene-tetrahydroflolate reductase (MTHFR),  
caused by cytosine (C) to thymine (T) point mutation leads to  substitution of  
 
valine for alanine
32
 . This mutation reduces MTHFR activity by about 50%, which  
 
predisposes to hyperhomocysteinemia. Homozygosity for MTHFR C677T has  
 
been found in mainly Caucasian and Hispanic people.Cystathione β-synthase  
 
deficiency and MTHFR deficiency are the other determinants that will lead to  
 
hyperhomocysteinemia. 
 
Other Associations 
Hypothyroidism  increases plasma homocysteine levels due to decreased renal  
 
function. Hyperhomocysteinemia has  also been noted in 
 
1.Rheumatoid arthritis [RA] 
 
2.Psoriasis 
 
3.Cancer, including breast, ovarian, and pancreatic cancer, and acute     
 
  lymphoblastic leukemia [ALL].  
 
The underlying mechanisms in in these conditions  causing  
 
hyperhomocysteinemia are not clear.  
 
 
Drugs
33 
 
Main drugs  causing hyperhomocystnemia are methotrexate ,phenytoin,  
 
carbamazepine, and valproic acid.Other drugs are theophylline, isoniazid, and  
 
hydralazine which act by inhibiting the synthesis of  pyridoxine. 
 
 
NORMAL HOMOCYSTEINE LEVEL
10 
 
The normal  plasma level of  homocysteine  in the  human body is 5–15 μmol/L.  
When the plasma homocysteine level >15 μmol/L there is hyperhomocystenemia 
and is classified as moderate (15–30 μmol/L), intermediate (30–100 μmol/L), and    
severe (>100 μmol/L). The prevalence of hyperhomocysteinemia  is between 5%  
and 10%.  
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HYPERHOMOCYSTENEMIA AND AGE RELATED PROBLEMS 
 
The various systems affected by increased homocysteine levels  and the proposed  
 
mechanisms  responsible for these effects are summarized in the diagram  which is  
 
shown below: 
 
 
 
 
                                  
 
 
 
 
Vascular Diseases 
Hyperhomocysteinemia is an independent risk factor for coronary artery disease.  
 
Hyperhomocystenemia  is a strong independent predictor of cardiac events  
 
and mortality and  morbidity in patients with angiographically confirmed  
 
coronary artery disease. Hyperhomocysteinemia plays an important role in the  
 
development of cerebrovascular disease, cerebral small-vessel disease or  
 
leukoaraiosis and peripheral vascular disease. 
 
CAD and MI 
Hyperhomocysteinemia   is associated with increased  prevalence of coronary  
 
artery disease and is also associated with increased  mortality and morbidity of  
 
cardiac patients. 
 
Stroke 
Hyperhomocysteinemia is  associated with increased  stroke prevalence, silent 
brain infarcts  and  cerebral white matter lesions (leukoaraiosis)
34
 .Increased 
homocysteine levels is a strong predictor for cerebrovascular disease in 
normotensive men.New silent infarcts seems to be increased  in persons with 
hyperhomocystenemia  and without  any previous infarcts.  
Carotid artery disease and peripheral arterial disease  
There is a significant  association between elevated homocysteine levels and 
extracranial carotid artery disease.Hyperhomocysteinemia predisposes to lower 
ankle–brachial index leading to peripheral atherosclerosis.  
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Pathophysiologic mechanisms of vascular disease in hyperhomocysteinemia 
A number of mechanisms have been proposed for the development of vascular 
disease in patients with hyperhomocysteinemia.The targets of homocysteine are  
1.endothelial cell  
2.platelet  
3.vascular smooth muscle cell 
4.blood lipids 
5.coagulation factors  
 6.nitric oxide.  
Homocysteine-induced    arteriosclerosis   is first   seen   as   endothelial   injury 
leading to   significant   platelet   activation   and  finally   by  thrombus  formation. 
Homocysteine  is   auto-oxidized  in  plasma,   leading   to  the  formation    of  
superoxide   and  hydrogen   peroxide   which  causes    endothelial  damage  and 
oxidative   modification   of low-density lipoprotein[LDL] , resulting  in   the 
formation   of   foam   cells. Homocysteine  also   promotes   the   proliferation  of 
vascular   smooth   muscle   cells   by    inducing   cyclin A   gene   expression  and 
hence   greatly   contributes   to   atherosclerosis.  
Homocysteine  also  creates a  prothrombotic   environment by  activating  factor 
V,   reducing   protein C  activation ,  inactivating the expression of 
thrombomodulin , inducing   expression  of   tissue factors  ,  suppressing   the 
anticoagulant   heparin  sulfate expression  ,  and  blocking  tissue  plasminogen 
activator     binding    to   endothelial   cells. Finally,   homocysteine   depletes   the    
endothelium-derived   nitric   oxide   and   reduces   its   production ,   further 
impairing    the   endothelial   function. 
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Cognitive Impairment 
Alzheimer's disease  and  vascular dementia accounts for most of the cases of  
 
dementia in the old and homocysteine which can act as a neurotoxin may act as a  
 
causative factor.Alzheimers and vascular dementia patients were detected to have  
 
higher levels of homocysteine .Hyperhomocysteneimia can also affect the  
 
cognition psychomotor speed ,thinking and memory of the patients. 
 
 
 
37
Depression 
The older population are very frequently  associated with depression    and  
 hyperhomocysteinemia  is found to be  associated with  depressive symptoms in  
 
old age.Depression itself can lead to anorexia and decreased food intake which and  
 
can lead to poor nutrition and vitamin deficiencies and thus lead to   
 
hyperhomocysteinemia.  
 
36
Osteoporotic Fracture 
The main characteristics of osteoporosis are decreased bone mineral density, which  
 
affects the bone microstructure  which predisposes to increased risk of fracture  
 
with more cases being reported in the elderly.Hyperhomocysteinemia is being  
 
noted in patients with osteoporosis.Hyperhomocysteinemia is also associated with   
 
increased with fractures since homocysteine distorts cross-linking of collagen , and  
 
thus can cause fractures. 
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HOMOCYSTEINE  LOWERING THERAPY 
 
The therapeutic options for lowering elevated homocysteine are : 
 
1.Folic acid 
 
2.Vitamin B6 
 
3. Vitamin B12 
 
4. S-adenosyl-methionine   
  
5. Zinc   
 
6. Inositol 
 
7. Choline  
 
8. Trimethylglycine (TMG)  
 
Folic acid   (0.5 to 5 mg/day)  decreases   homocysteine    levels  by  25%  in  
 
patients with   high   homocysteine levels. Vitamin   B12    produces   a   small  
 
additional   effect (7%),   whereas    vitamin B6    treatment   alone    only   reduces  
 
post-methionine    load. Betaine   (trimethylglycine)   reduces   fasting  
 
homocysteine   by  12 %  to   20%.  
 
 
 
 
 
 
 
 
 
METHODS AND MATERIALS: 
This study was done at Government Royapettah Hospital, Chennai for a 
 
period of six months from Febraury 2015 to July  2015. The study was 
 
performed after procuring informed written consent from all the participants 
 
involved. Clearance was obtained from the Ethical Committee of the 
 
Government  Kilpauk  Medical College & Hospital Chennai. 
 
 
STUDY DESIGN: 
 
The study design is a case control study. 
 
POPULATION: 
Study group  : Cases were patients admitted with acute ischemic stroke in ward  
 
and compared  with  controls 
    .    
METHODOLOGY: 
Patients admitted to medical ward with acute ischemic stroke clinic  were 
assessed after obtaining written informed consent.Clinical data was obtained from the  
patient.Serum homocysteine levels,random blood sugar,serum cholesterol and blood  
pressure was measured in each patient and their controls  and compared according to  
the different classes. 
 
 
 INCLUSION CRITERIA 
 1.Clinical evidence of stroke 
 2.Cranial computed tomography (CT) scan or MR imaging consistence with                                 
     ischemic stroke 
EXCLUSION CRITERIA  
1. Patients with CT scan or MR imaging showing hemorrhage or mass lesion  
2.Patients with previous history stroke 
3.Patients with coronary artery disease  
4.Patients with vasculitis  
5.Patients with other liver and renal diseases 
6.Patients with multiple risk factors 
7.Patient taking multi vitamin tablets 
 
DATA COLLECTION 
 
The data of each patient was collected on a proforma specially designed  
 
for this study and which includes clinical features, past medical history and the  
 
presence of any risk factors. The clinical data obtained  will be analysed for  
 
statistical significance and correlation. 
 
SAMPLE SIZE 
         As per formula, sample size was calculated to be 50 case with 50 controls. 
 
 
  
      
     STATISTICAL      
       ANALYSIS  
 STATISTICAL ANALYSIS 
 
The statistical analysis was obtained using the SPSS software. 
 
1. AGE DISTRIBUTION OF CASES 
 
 
      
 
 
From the above graph,it is clear that most of the stroke cases was segregated  in the  
 
middle of the graph.16 cases were seen in the 61 – 70 age group,12 cases in 51 -60  
 
and 71-80 age group.5 cases were in the age group of 81 and above.Only 1case  
 
was seen in  41 -50 age group and 4 cases in 31- 40 age group.No cases were  
 
present in 20- 30 age group. Hence we can see that most of the cases are in the  
 
elderly age group. 
 
 
 
0
2
4
6
8
10
12
14
16
18
NO OF CASES
20-30
31-40
41-50
51-60
61-70
71-80
81 AND ABOVE
 2.SEX DISTRIBUTION IN CASE AND CONTROL 
  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
From the table and graph above ,it is inferred that males make up 68% of the case  
 
ie 34 of the 50 cases which confirms that ischemic stroke is more prevalent in the  
 
male population. 
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Sex 
  
  
Group 
Total 
  
P value 
Control Cases 
Male 
  
  
Count 29 34 63  
 
 
 
 
 
 
 
0.300 
% within Sex 46.0% 54.0% 100.0% 
% within 
Group 
58.0% 68.0% 63.0% 
Female 
  
  
Count 21 16 37 
% within Sex 56.8% 43.2% 100.0% 
% within 
Group 
42.0% 32.0% 37.0% 
 Total Count 50 50 100 
% within Sex 50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 3.RISK FACTORS IN CASES 
 
 
 
 
The above graph shows the percentage of risk factors contributing to ischemic  
 
stroke cases with hypertension being predominant ,present in about 22 cases  
 
(44%), diabetes in 15 cases (30%) and dyslipidaemia in 12 cases(24%).No risk  
 
factors were detected in 1 case(2%). 
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 4.RISK FACTOR IN CONTROLS 
 
 
 
 
 
Among the control , hypertension contributes 21 cases(42%),diabetes 11  
 
cases (22%),dyslipidaemia 7 cases(14%) and cases with no risk factors 11 in  
 
number(22%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERCENTAGE OF RISK FACTORS IN CONTROLS 
HYPERTENSION
DIABETES
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NO RISK FACTORS
 5.DISTRIBUTION OF RISK FACTORS REGARDING SEX 
 
a)HYPERTENSION 
 
                               
 
From the table  above ,it seen that hypertension is present in 19 male cases and  
 
only 3 female cases and was present in 18 male controls and 3 female controls.  
 
Hence hypertension was more common in the males both  cases  and controls. 
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b)DIABETES 
 
 
                  
 
From the graphs above ,it is noticed that diabetes was present in 7 male case and 8  
 
female cases ,but was absent in any male controls and present in11 female controls. 
 
Hence, it is observed that diabetes was observed more in the female population in  
 
the  study sample.  
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c)DYSLIPIDAEMIA 
 
 
                       
 
                                              
                          
The above graphs shows that in the study dyslipidaemia was present in 7 males and  
 
5 females among the cases and in 5 males and 2 females among the controls.This  
 
shows that dyslipidaemia was more common in the male population in the study  
 
group. 
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6.PRESENCE OF HYPERHOMOCYSTENEMIA 
 
  
  
  
  
Group Total P value 
Control Cases    
 
 
 
 
 
 
 
 
 
Less than 
0.001** 
Hyperhomocysteine
mia 
Present Count 
1 15 16 
  
  
  
  
  
  
  
% within 
Hyperhomocysteine
mia 
6.3% 93.8% 100.0% 
% within Group 2.0% 30.0% 16.0% 
Absent 
  
  
Count 49 35 84 
% within 
Hyperhomocysteine
mia 
58.3% 41.7% 100.0% 
% within Group 98.0% 70.0% 84.0% 
                                     Total 
  
  
Count 50 50 100 
% within 
Hyperhomocysteine
mia 50.0% 50.0% 100.0% 
% within Group 100.0% 100.0% 100.0% 
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The above table shows the presence of hyperhomocystenemia in cases and  
 
controls.Hyperhomocystenemia is present in 30 % of the cases and only in 2 % of  
 
the  controls and was absent in 70 % of the cases and 98% of the controls with  
 
significant statistical correlation and which shows the association of  
 
hyperhomocystenemia with stroke. 
 
 
7.HYPERHOMOCYTEINEMIA AND SEX DISTRIBUTION 
 
Group     Hyperhomocysteinemia Total 
P VALUE 
    Present Absent   
 
 
 
 
 
 
 
 
 
 
0.300 
Control 
  
  
  
  
  
Sex 
  
  
  
  
  
Male 
  
  
Count 1 28 29 
% within Sex 3.4% 96.6% 100.0% 
% within 
Hyperhomoc
ysteinemia 
100.0% 57.1% 58.0% 
Female 
  
  
Count 0 21 21 
% within Sex .0% 100.0% 100.0% 
% within 
Hyperhomoc
ysteinemia 
.0% 42.9% 42.0% 
  
Total 
  
  
Count 1 49 50 
% within Sex 2.0% 98.0% 100.0% 
% within 
Hyperhomoc
ysteinemia 
100.0% 100.0% 100.0% 
Cases 
  
  
  
  
  
Sex 
  
  
  
  
  
Male 
  
  
Count 11 23 34 
% within Sex 32.4% 67.6% 100.0% 
% within 
Hyperhomoc
ysteinemia 
73.3% 65.7% 68.0% 
Female 
  
  
Count 4 12 16 
% within Sex 25.0% 75.0% 100.0% 
% within 
Hyperhomoc
ysteinemia 
26.7% 34.3% 32.0% 
  
Total 
  
  
Count 15 35 50 
% within Sex 30.0% 70.0% 100.0% 
% within 
Hyperhomoc
ysteinemia 
100.0% 100.0% 100.0% 
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 From the above table and graph we can infer that though not statistically  
 
significant,hyperhomocysteinemia is present in 32.4% of the male cases and 25%  
 
of the female cases. 
 
Males make up  73.3% of the hyperhomocysteinemia cases and females just 26.7%  
 
of  the  hyperhomocysteinemia cases. 
 
In the controls,hyperhomocysteinemia is noted in 3.4 % of the male controls and  
 
absent in 96.6%  while in the female controls,hyperhomocysteinemia is absent in  
 
all. 
 
8.HOMOCYSTEINE LEVEL 
 
  
A)CASES AND CONTROLS 
 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
 P value 
Homocysteine 
Level 
Control 
50 7.36 1.871 .265 
 
  Cases 50 16.22 6.274 .887 0.001** 
 
 
 B)MALE CASE AND CONTROLS 
 
 
 MALE N Mean Std. Deviation 
Std. Error 
Mean 
P value 
Homocysteine 
Level 
Control 
29 7.55 2.245 .417 
 
  Cases 34 16.82 6.626 1.136 0.001** 
 
 
 
 
 
  
C)FEMALE CASE AND CONTROLS 
 
 FEMALES N Mean Std. Deviation 
Std. Error 
Mean 
 
P value 
Homocysteine 
Level 
Control 
21 7.10 1.179 .257 
 
0.001** 
 
  Cases 16 14.94 5.422 1.355  
 
 
 
 
D)ALL MALES AND FEMALES 
 
 
Sex (both case 
and controls) N Mean Std. Deviation 
Std. Error 
Mean 
P value 
Homocysteine 
Level 
Male 
63 12.56 6.881 .867 
 
  Female 37 10.49 5.342 .878 0.119 
 
 
The mean homoysteine level in the cases is 16.32 and in the controls is 7.36 which  
 
is statistically significant with p value less than 0.05 which showed that that  
 
hyperhomocysteinemia is indeed a risk factor for stroke.Mean homocysteine value   
 
is 16.82  in male cases and  7.55  in male controls.The mean homocysteine value     
 
is 14.94 in female cases and 7.10 in female control which shows that homocysteine  
 
levels were significantly higher in male and female case than controls.Mean  
 
homocysteine levels were slightly higher in males than in females(both case and  
 
controls)  but it was not statistically significant.  
 
 
 
 
  
9.RISK  FACTORS  CONTRIBUTING TO HYPERHOMOCYSTENEMIA 
 
 
 
From the above pie chart, it is clear that most of the hyperhomocystenemia cases  
 
were associated with hypertension (36.4%),followed by diabetes (26.7%),and  
 
finally dyslipidaemia(25%).1 case of hyperhomocystenemia had no history of   
 
hypertension,diabetes or dyslipidaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
PERCENTAGE OF RISK FACTORS 
CONTRIBUTING TO 
HYPERHOMOCYSTENEMIA 
HYPERTENSION
DIABETES
DYSLIPIDAEMIA
 A)HYPERTENSION GROUP COMPARISION 
 
Hypertension   Group Total P value 
    Control Cases    
 Present Count 21 22 43 
    % within 
Hypertension 
48.8% 51.2% 100.0% 
 
 
    % within Group 42.0% 44.0% 43.0%  
  Absent Count 29 28 57 0.840 
    % within 
Hypertension 
50.9% 49.1% 100.0% 
 
    % within Group 58.0% 56.0% 57.0%  
Total Count 50 50 100  
  % within 
Hypertension 
50.0% 50.0% 100.0% 
 
  % within Group 100.0% 100.0% 100.0%  
 
 
 
 
 
 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
P value  
Homocysteine 
Level 
Control 
21 7.43 1.399 .305 
0.001** 
  Cases 22 17.82 6.877 1.466  
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The above tables shows that hypertension is present in 44% and absent in 56% of  
 
the cases and present in 42% of the cases and absent in 58% of the controls.The  
 
mean value of homocysteine in hypertensive case and control is 17.82 and 7.43  
 
respectively which shows that homocysteine is increased in hypertensive ischemic  
 
stroke patients.  
 
 
 
B)DIABETES GROUP COMPARISION 
 
 
 
  
  
  
Group Total P value 
Control Cases   
 
 
 
 
 
 
 
0.362 
Diabetes Present Count 11 15 26 
  
  
  
  
  
  
% within 
Diabetes 
42.3% 57.7% 100.0% 
% within 
Group 
22.0% 30.0% 26.0% 
Absent 
  
  
Count 39 35 74 
% within 
Diabetes 
52.7% 47.3% 100.0% 
% within 
Group 
78.0% 70.0% 74.0% 
Total 
  
  
Count 50 50 100 
% within 
Diabetes 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 
 
  
 
 Group N Mean Std. Deviation P VALUE 
Homocysteine 
Level 
Control 11 7.36 1.120 0.001** 
Cases 15 15.20 5.583  
 
 
From the above tables we can infer, that  diabetes is present in 30% of the cases  
and absent in 70% of the cases and present in 22% of the controls and absent in  
78% of the cases.The mean value of homocysteine in diabetic case is 15.20 and  
control is 7.36 which is statistically significant.   
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c)DYSLIPIDAEMIA GROUP COMPARISION 
 
  
  
  
Group Total P value 
Control Cases   
 
 
 
 
 
 
0.202 
 
Dyslipidaemia 
  
  
  
  
  
Present 
  
  
Count 7 12 19 
% within 
Dyslipidaemia 36.8% 63.2% 100.0% 
% within Group 14.0% 24.0% 19.0% 
Absent 
  
  
Count 43 38 81 
% within 
Dyslipidaemia 
53.1% 46.9% 100.0% 
% within Group 86.0% 76.0% 81.0% 
Total 
  
  
Count 50 50 100 
% within 
Dyslipidaemia 
50.0% 50.0% 100.0% 
% within Group 100.0% 100.0% 100.0% 
 
 
 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
P VALUE 
Homocysteine 
Level 
Control 
7 6.43 1.134 .429 
 
  Cases 12 14.92 5.946 1.716 0.001** 
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 From the above graph and table it is clear that dyslipidaemia is present in 24 %   
and absent in 76% of the cases and present in 14 % and absent in 86% of the  
controls.The mean value of homocysteine level in case was 14.62 and controls was  
6.43 which was statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
DISCUSSION 
1.AGE DISTRIBUTION OF THE CASES 
The mean age of the case  is 65.46 with most of the cases clustered in the elderly  
 
age group.It was seen that most of the cases ie 16 cases were seen in the 61 – 70  
 
age group,12 cases in 51 -60 and 71-80 age group each which shows that ischemic  
 
stroke usually occurs in the elderly population which is comparable with the study  
 
done by Tomassina et al
16
 and according to the national stroke registry  the crude  
 
prevalence rate of stroke in Indian is about 22 per 100000 persons
17
. 
 
2.SEX DISTRIBUTION IN CASES 
68% of the ischemic stroke cases under study were males compared to females,  
which confirms that the male sex was at a higher risk to suffer from ischemic  
stroke which may be due to the fact that a higher percentage of male population  
will be having one or the other risk factors such as hypertension,diabetes,  
dyslipidemia, smoking or alcoholism.This was in concordance with the study done  
by Peter Appelros et al
15
.  
 
3.DISTRIBUTION OF RISK FACTORS WITH RESPECT TO SEX 
Hypertension was found to be more common in the male population in this study  
compared to females and could be due to the smoking and alcoholic habits of the  
male population which by  themselves increase the blood pressure and are  
independent risk factors for cardiac diseases.Diabetes was found to more common  
in female population in this study and dyslipidemia was found to be more common  
in the male population according to this study. 
4.  HYPERHOMOCYSTENEMIA AND STROKE 
It was seen that  hyperhomocystenemia was present in 30% of the cases compared  
to 2% of the controls which is comparable to other studies such as Vekat
12
 et al  
who found out 40% association in case and 4%in controls which indeed shows that  
hyperhomocystenemia is a risk factor for stroke.This was also comparable to other  
studies done by Orman et al and Eikelboom
11
  et al. 
The mean value of homocysteine in case was much higher in case than  
control(16.22 compared to 7.36) which further cements the stroke causative ability  
of elevated homocysteine and hence, we can find a strong correlation between  
homocysteine and ischemic stroke which is in concordance with Parnetti et al
13
. 
Most of the hyperhomocysteinemia cases were males(73.7%) compared to (27.3)  
in  the females.The mean value among male cases was 16.82 and among females  
cases was 14.94 which although not statistically significant shows that  
hyperhomocysteinemia was more common in males which was in concordance  
with the study done by Carod-Artal et al
14
.The mean homocysteine value is much  
higher in both  male and female cases than controls. 
Although this study found a strong correlation between hyperhomocystenemia and  
ischemic stroke,some studies have failed to do so.Another point to note is that  
there is no definite level of homocysteine above which there is drastic increase in  
vascular events,since some studies showed that stroke and other vascular  
compications can also occur within normal range of homocysteine levels. 
 
5.HYPERHOMOCYSTEINEMIA AND RISK FACTORS 
It was seen from the study that hypertension is present in 44%  of the cases and the  
 
mean value of homocysteine in hypertensive case was 17.82,  much higher than  
 
controls which shows that homocysteine is increased in hypertensive ischemic  
 
stroke patients. The strong association between hypertension and ischemic stroke  
 
was also seen by Carot-Artal et al
14
.Hyperhomocysteinemia may lead to the loss of  
 
serine elastase which is very important for the maintenance of elasticity of the  
 
arterial wall and due to the loss of  arterial elasticity and hence leads to  
 
hypertension. 
 
 
The study shows that diabetes is present in 30% of the cases and the mean value of  
homocysteine in diabetic case is 15.20 and control is 7.36 which is statistically  
significant which is in concordance with Van Guldener et al
39
, and also  
dyslipidemia is present in 24 %   cases and and the mean value of homocysteine  
level in case was 14.62 and controls was 6.43 which was statistically significant  
which is in concordance with Xiaoyong et al
40
. 
 
 
 
 
 
CONCLUSION 
1.Incidence of stroke is higher in the middle age and old age group. Most of the  
 
   cases ie 16 cases were seen in the 61 – 70 age group,12 cases in 51 -60 and 71-80  
 
   age group each . 
 
2.Incidence of stroke is higher in the male population but prevalence is higher in  
   the female population due to their longevity.68% of the stroke cases were male  
   patients, which showed the higher incidence of stroke in male population. 
 
3.The homocysteine level was  higher in the stroke cases compared to the controls 
    which shows that homocysteine is a risk factor for ischemic stroke.The mean  
    homocysteine level  was 16.22 compared to7.36  in the controls. 
 
4.Homocysteine level is higher in male cases than female cases.Mean  
    homocysteine levels in  males  was 16.82 and  in females was14.94 
 
5.A number of risk factors are associated with increased homocysteine  
   level.Hyperhomocysteinemia is asscociated in stroke cases with hypertension,  
   diabetes,dyslipidiaemia.Among the risk factors,hypertension was more common  
  male cases and controls than females,diabetes was common in the female cases    
  and controls and dyslipidaemia was more common in male cases and controls   
  than females 
 
Hyperhomocystenemia is a risk factor for ischemic stroke especially in the younger  
age which is usually not associated with any risk factors.A large number of the  
younger  population should be screened for their homocysteine levels and if found  
to be high, adequate supplementation of vitamin b12 and folate should be given.  
Also homocysteine levels are determined by genetics,pharmacology,nutrition and  
pathology the homocystein levels of the Indian population are very different  
compared to the western population and large number of large scale trials are    
needed to determine the homocysteine status of the Indian population 
 
LIMITATIONS OF THE STUDY 
 
1.Small number of cases and controls 
2.Cases and controls with multiple risk factors were excluded 
3.Levels of vitamin b12 and folate level were not measured in the patients since  
   their deficiency can itself lead to hyperhomocystenemia. 
4.Homocysteine levels were measured after stroke so it was not able to ascertain    
   whether homocysteine was the cause of stroke or whether  it was a consequence     
   of stroke. 
5.Smoking and alcoholism as a risk factor was not taken into account. 
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